Vitamin B7, Biotin
Biotin is a B-complex essential vitamin that takes an important role in hair, nails and skin health. It is a water-soluble component which also works as an coenzyme in the insulin and glucose metabolism.
- Origin: Plant Based, Animal Product
- Source: Eggs, Meat, Fish, Beans, Fruits, Vegetables, Carrots, Peanuts, Walnuts, Almonds, Hazelnut, Oatmeal, Bananas
- Type: Vitamin, Co-enzyme
- Age Range: Adults (18-60), Seniors (>60)
- Toxicity: There is no evidence of toxicity until now
- Outcomes: Diabetes & Blood Sugar, Blood Sugar Control
What are Biotin benefits?
Biotin is one of the essential B vitamins that the human body uses mainly as a cofactor for enzymes. It is essential for the production of glycogen, nucleic acids, and amino acids, and participates in the production of white blood cells and antibodies. It increases the use of vitamin B12, B5, and folic acid, and helps strengthen hair loss. It regulates saturated fat (cholesterol) levels, reduces muscle pain and cramps, and is important for the treatment of eczema and dermatitis. Some foods are rich in biotin, such as: egg yolks, legumes, nuts and seeds, liver, sweet potatoes, mushrooms, bananas, and broccoli. Biotin supplementation is essential to keep your body functioning at its best, take our 3-step test to get the best indication.
Table of relations
Published articles about Biotin and Blood Sugar Control
6 months of treatment with 2g inositol to women with hirsutism was associated with reductions in the symptoms directly as well as improvements in insulin sensitivity.
The Combined Therapy With Myo-inositol And D-chiro-inositol Reduces The Risk Of Metabolic Disease In PCOS Overweight Patients Compared To Myo-inositol Supplementation Alone
Supplementation of myo-inositol by itself at 2g daily for a period of six months in women with PCOS was associated with improvements in diastolic blood pressure. The combination with D-chiroinositol was the same at a lower dose (550mg and 13.8mg, respectively) when measured at six months, but seemed to act faster as inositol at 2g required six months to be fully effective.
Effects Of Inositol On Ovarian Function And Metabolic Factors In Women With PCOS: A Randomized Double Blind Placebo-controlled Trial
200mg of inositol daily (in two divided doses of 100mg) for a period of 12 weeks in women with PCOS was ineffective in improving the glucose metabolic markers yet was effective in reducing body weight and improving fertility.
Metabolic And Hormonal Effects Of Myo-inositol In Women With Polycystic Ovary Syndrome: A Double-blind Trial
Supplementation of 4,000mg inositol daily for a period of 12-16 weeks in women with PCOS was able to improve tolerance to glucose and glucose handling (as well as reduce the amount of insulin secreted in response to a meal) with minor benefits to cardiovascular health as well.
Supplementation of myo-inositol at 2g twice daily for the course of one year in postmenopausal women with metabolic syndrome was associated with improvements on all metabolic parameters measured (cardiovascular health and glucose metabolism) although no influence on weight was noted.
Inositol Administration Reduces Oxidative Stress In Erythrocytes Of Patients With Polycystic Ovary Syndrome
Supplementation of 1,200mg Myo-inositol daily for a period of 12 weeks in normal weight women (22-30yrs) with PCOS was able to decrease weight (−1.83+/-1.86kg, very unreliable in magnitude) and improved markers of glucose and androgen metabolism. An improvement in oxidative biomarkers was also noted (GSH in red blood cells).
Randomized, Double Blind Placebo-controlled Trial: Effects Of Myo-inositol On Ovarian Function And Metabolic Factors In Women With PCOS
4g of inositol daily for a period of 16 weeks in women with PCOS was ineffective in improving parameters of insulin sensitivity while it was sufficient to improve biomarkers of steroid metabolism and fertility. Weight was decreased in all subjects who were not morbidly obese.
Differential Insulin Response To Myo-inositol Administration In Obese Polycystic Ovary Syndrome Patients
Supplementation of 2,000mg inositol (INOFERT) once daily for eight weeks in obese women with PCOS was able to improve insulin sensitivity and other biomarkers of glucose metabolism only in those with higher circulating insulin concentrations. No placebo control was used in this study.
Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome
Two weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.
5g psyllium taken thrice a day for 6 weeks was able to significantly reduce glucose and all improve all parameters of a lipid panel in diabetic persons relative to placebo; treatment was well tolerated.
Supplementation of 14g of psyllium fiber daily for six weeks was associated with a significantly reduced absorption of glucose (12.2%) and a reduction in other parameters of glucose metabolism including insulin (5%), HbA1c (3.8%), 24-hour urinary glucose (22.5%), fructosamine (), and uric acid (10.9%). Some improvements were also noted in the lipid profile.
Cholesterol-lowering Effects Of Soluble-fiber Cereals As Part Of A Prudent Diet For Patients With Mild To Moderate Hypercholesterolemia
Supplementation of 10g psyllium husk via cereal in persons with high cholesterol for 6 weeks failed to influence hematological parameters and body weight while reducing total cholesterol and LDL-C.
Effects Of Dietary Fiber And Low Glycemic Index Diet On Glucose Control In Subjects With Type 2 Diabetes Mellitus
Assessment of 7 trials using psyllium supplement and/or a low glycemic diet for diabetes management concluded that psyllium was possibly useful as an adjuvant treatment for blood glucose and HbA1c in diabetics on drugs who may require further therapy to reduce glucose.
In diabetic patients, Berberine at 0.5-1.5g daily for an average period of 12 weeks was associated with minor to moderate improvements on all measured glucose and lipid parameters; rivalling oral hypoglycemics in potency
Berberine in isolation at 1g for 3 months was able to reduce triglycerides and fasting glucose levels in type II diabetics. Total cholesterol and LDL also decreased, and an increase in glucose disposal rate was seen. Insulin sensitivity showed a trend for improvement, but did not reach statistical significance.
184 patients with nonalcoholic fatty liver disease were randomized to one of three arms for 16 weeks: lifestyle intervention alone, lifestyle interventions plus 15mg pioglitazone daily, or lifestyle interventions plus 0.5g berberine three times a day. Berberine plus lifestyle changes significantly improved liver fat content, BMI, HOMA-IR, total cholesterol, and triglycerides significantly more than lifestyle interventions alone. The berberine group tended to have minor digestive issues that tended to resolve 2 weeks into the study.
Effect Of Berberine Administration On Metabolic Syndrome, Insulin Sensitivity, And Insulin Secretion
24 people with metabolic syndrome were randomized to placebo or 0.5g berberine three times a day for three months. Decrease in waist circumference in females only, systolic blood pressure, triglycerides, area under the curve of glucose and insulin, and Matsuda index were all seen to be significant in the berberine group versus placebo.
Biotin Supplementation Reduces Plasma Triacylglycerol And VLDL In Type 2 Diabetic Patients And In Nondiabetic Subjects With Hypertriglyceridemia
Supplementation of 15mg biotin in subjects with high triglycerides, with or without type II diabetes, appeared to reduce serum triglycerides and vLDL over the course of 28 days therapy. There were no other biochemical changes noted, and while there was a trend to reduce BMI it did not reach significance.
Supplementation of chromium to type II diabetics for 28 weeks noted a reduction in blood glucose relative to baseline and placebo, and the minor changes in HbA1c and insulin turned out to be significant due to an increase seen in placebo. Weight and blood pressure were not significantly different, nor were any parameter of lipid metabolism measured.
The Effects Of Inorganic Chromium And Brewer's Yeast Supplementation On Glucose Tolerance, Serum Lipids And Drug Dosage In Individuals With Type 2 Diabetes
Low dose chromium supplementation (23.3mcg) via Brewer's Yeast and 200mcg chromium as trichloride for eight weeks in type II diabetics both appeared to reduce both fasting and postprandial blood glucose (75g glucose tolerance test) and was able to reduce fructosamine as well.
The Influence Of Chromium Chloride-containing Milk To Glycemic Control Of Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial
The addition of 200mcg chromium (as chloride) to milk powder, relative to a milk powder placebo, in type II diabetics already on medication (gliclazide) noted that there was a reduction in blood glucose, insulin, and improvement in insulin sensitivity over the course of 16 weeks in men only. Acute insulin response following an oral glucose tolerance test (10 minutes after) was unaffected in both sexes.
Elevated Intakes Of Supplemental Chromium Improve Glucose And Insulin Variables In Individuals With Type 2 Diabetes
4 months supplementation of 200mcg or 1,000mcg chromium (as picolinate) in type II diabetics was able to reduce fasting and postprandial blood glucose (higher dose only), fasting and postprandial insulin (both groups equally), HbA1c (higher dose only), and total cholesterol (higher dose only) with no influence on HDL nor body weight.
In overweight women reporting intense carbohydrate cravings at least twice a week, supplementation of 1,000mcg chromium appeared to reduce hunger and cravings over the course of weight weeks which resulted in a greater reduction in overall food intake (25%) than did placebo (8%). This reduction in food intake led to weight loss, but was independent of any changes in glucose metabolism.
A Double-blind, Randomized Pilot Trial Of Chromium Picolinate For Binge Eating Disorder: Results Of The Binge Eating And Chromium (BEACh) Study
Six months supplementation of chromium as picolinate (600µg or 1000µg) was able to nonsignificantly reduce symptoms of binge eating disorder (binge frequency) and weight relative to placebo, while HbA1c and blood glucose also failed to reach statistically significant reductions despite trends to do so.
Effects Of Short-term Chromium Supplementation On Insulin Sensitivity And Body Composition In Overweight Children: Randomized, Double-blind, Placebo-controlled Study
400mcg chromium given to overweight children who were also given exercise and diet plans (relative to diet and exercise paired with placebo) over the course of six weeks failed to reduce bodyweight relative to placebo (at the P level of 0.05) but the reduction in fat mass and increase in lean mass was greater with chromium than with placebo. Insulin sensitivity was improved to a statistically significant degree, but no other health variable was beneficially influenced.
Effect Of Resistance Training With Or Without Chromium Picolinate Supplementation On Glucose Metabolism In Older Men And Women
In otherwise healthy but overweight aged adults, the combination of chromium plus resistance training (relative to placebo and training) over 13 week dosed at 1,000mcg failed to augment the benefits of exercise (in reducing insulin AUC following an oral glucose tolerance test) and did not exert any hypoglycemic actions.
Influence Of Chromium-enriched Yeast On Blood Glucose And Insulin Variables, Blood Lipids, And Markers Of Oxidative Stress In Subjects With Type 2 Diabetes Mellitus
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium. Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.
Supplementation of 1,000mcg chromium daily for three months in type II diabetics was able to shorten QTc intervals, suggesting a cardioprotective effect (as prolonged QTc intervals are indicative of cardiovascular mortality). Aside from insulin (which was also reduced), no other parameter was influenced.
Antioxidant Effects And Insulin Resistance Improvement Of Chromium Combined With Vitamin C And E Supplementation For Type 2 Diabetes Mellitus
In type II diabetics with an HbA1c over 8.5% given 1mg of chromium via yeast, supplementation was associated with a reduction in blood glucose (11%) and HbA1c (0.7%, from 10.2% to 9.5%) alongside an increase in insulin sensitivity. Lipid peroxidation, as assessed by TBARS, was also reduced with chromium by 18.7%. An increase in glutathoine peroxidase was noted, but catalase and SOD were unaffected.
In 11 middle aged obese women given 400mcg chromium (as picolinate) daily for eight weeks, there was no observable change in the anti-HMdU antibody suggesting no DNA damage from supplementation.
Effect Of Chromium On Glucose And Lipid Profiles In Patients With Type 2 Diabetes; A Meta-analysis Review Of Randomized Trials
A meta-analysis on chromium in type II diabetics where supplementation lasted for over three months noted that, relative to placebo, there was a mild but significant reduction in blood glucose. HbA1c and all biomarkers of lipid metabolism, as well as weight, were all unaffected. This meta-analysis was restricted to type II diabetics and the duration of at least three months, but at times included studies containing chromium enriched yeast and biotin supplementation alongside the chromium.
Characterization Of The Metabolic And Physiologic Response To Chromium Supplementation In Subjects With Type 2 Diabetes Mellitus
Supplementation of 1mg chromium (in the form of chromium picolinate) in two divided doses daily for 24 weeks in type II diabetics noted that while there was a trend to increase insulin sensitivity, this was not statistically significant and only 46% of persons were considered responders. No other changes were noted in diet, glucose metabolism, and the response to chromium was more associated with baseline insulin resistance rather than the kinetics of chromium after ingestion.
Chromium Supplementation Does Not Improve Glucose Tolerance, Insulin Sensitivity, Or Lipid Profile: A Randomized, Placebo-controlled, Double-blind Trial Of Supplementation In Subjects With Impaired Glucose Tolerance
Supplementation of 400mcg chromium (as picolinate) twice daily in obese participants with impaired glucose tolerance failed to exert any appreciable benefit relative to placebo over the course of three months.
The addition of 400 or 800μg chromium (as picolinate) to a test meal containing 75g carbohydrate from breads noted that there was no significant influence on postprandial metabolism when assessing the whole group, but the subjects could be divided into responders and nonresponders where said responders reduced the glucose AUC by 30-36% (lower dose being more effective). Insulin was not affected in any person, and the nonresponders appeared to have a more meat and milk based diet than a plant based one. Nonresponders also had a significantly higher iron and transferrin content in the blood (transferrin saturation and ferritin content similar).
The Effects Of Inorganic Chromium And Brewer's Yeast On Glucose Tolerance, Plasma Lipids, And Plasma Chromium In Elderly Subjects
In otherwise healthy free living adults, supplementation of chromium either as trichloride (200mcg chromium) or as yeast (5g yeast containing 10.8mcg chromium) failed to significantly influence any measured parameter in the blood despite an increase of chromium in the blood from trichloride including glucose tolerance to an oral glucose tolerance test.
Beneficial Effects Of Oral Chromium Picolinate Supplementation On Glycemic Control In Patients With Type 2 Diabetes: A Randomized Clinical Study
In older adults with evidence of memory decline, 1,000mcg chromium (as picolinate) daily for 12 weeks failed to influence glucose metabolism and did not influence depressive symptoms. Despite no influence on memory over the 12 weeks, there appeared to be significantly less inclusion errors during testing and increased activity in some regions of the right half of the brain during memory testing.
Supplementation of 1mg chromium as picolinate in obese adults over the course of 24 weeks failed to influence body weight either alone or in combination with nutritional education (teaching participants to eat better) and no other parameter in the blood or via CT scans was modified with supplementation.
Chromium Effects On Glucose Tolerance And Insulin Sensitivity In Persons At Risk For Diabetes Mellitus
Supplementation of chromium picolinate at 500mcg or 1,000mcg for six months in persons at risk for type II diabetes has failed to influence any biomarkers of glucose metabolism and was said to not confer any protection against the development of type II diabetes.
Supplementation of 600mcg chromium daily for a month failed to significantly modify glycogen depletion, concentrations, or resynthesis rates surrounding exercise in untrained or minorly trained men relative to placebo. Lactate AUC was higher with chromium intake relative to placebo.
Effects Of Carbohydrate And Chromium Ingestion During Intermittent High-intensity Exercise To Fatigue
In otherwise active men given a carbohydrate drink with or without an additional 400mcg chromium (as picolinate) subject to a shuttle run test an hour after the drink, the addition of chromium failed to significantly alter any change that carbohydrate was able to induce relative to water control suggesting no additional benefit.
Chromium Treatment Has No Effect In Patients With Type 2 Diabetes In A Western Population: A Randomized, Double-blind, Placebo-controlled Trial
Six months supplementation of chromium at 400mcg via enriched yeast to type II diabetics already on medications failed to confer any additional benefits, particularly the primary outcome (to see if a 0.5% reduction in HbA1c was reached).
Chromium Picolinate Supplementation Attenuates Body Weight Gain And Increases Insulin Sensitivity In Subjects With Type 2 Diabetes
Supplementation of 1,000µg chromium (as picolinate) alongside sulfonylurea therapy for 10 months in type II diabetic persons noted that, relative to a sulfonylurea/placebo pairing, that chromium resulted in an additional decrease in glucose and free fatty acids in serum without any other significant alterations. There appeared to be an anti-obese effect of chromium, as the 0.9kg weight gain with sulfonylurea therapy was mitigated with chromium coingestion.
Beneficial Effect Of Chromium Supplementation On Glucose, HbA1C And Lipid Variables In Individuals With Newly Onset Type-2 Diabetes
Supplementation of brewers yeast (conferring 42 μg chromium) in newly diagnosed diabetics for three months was able to significantly reduce blood glucose (47.6%), HbA1c (from 9.5% to 6.8%), and systolic blood pressure (12%) while causing some benefit to all lipid parameters except vLDL and HDL relative to placebo.
Chromium supplementation at 1,000mcg daily (as picolinate) increased the acute insulin response to glucose but failed to influence any other measured parameter of metabolic syndrome after 16 weeks supplementation in adults with signs of metabolic syndrome yet no diagnosed diabetes.
Effects Of Chromium Brewer's Yeast Supplementation On Body Mass, Blood Carbohydrates, And Lipids And Minerals In Type 2 Diabetic Patients
In obese type II diabetic subjects given trivalent chromium supplementation via Brewer's Yeast (500mcg chromium) for eight weeks, supplementation was able to exert a minor hypoglycemic effect which failed to reach statistical significance (P=0.08) while trends on other biochemical parameters failed to reach statistical significance.
In Patients With HIV-infection, Chromium Supplementation Improves Insulin Resistance And Other Metabolic Abnormalities: A Randomized, Double-blind, Placebo Controlled Trial
Supplementation of 400mcg chromium (as nicotinate) daily for 16 weeks in persons with HIV who were insulin resistant due to antiretroviral therapy appeared to improve insulin sensitivity and some other measured parameters such as triglycerides and weight when used as adjuvant.
Impact of cooking and digestion, in vitro, on the antioxidant capacity and anti-inflammatory activity of cinnamon, clove and nutmeg
Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial
Effect of ground cinnamon on postprandial blood glucose concentration in normal-weight and obese adults
The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions
Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study
200mg of Panax Ginseng, taken acutely one hour before endurance testing, was unable to increase physical performance in runners. Lactate production was reduced when measured 60 minutes after the start of exercise.
Korean Red Ginseng (Panax Ginseng C.A. Meyer) Root Fractions: Differential Effects On Postprandial Glycemia In Healthy Individuals
Korean Red Ginseng, given in a cross-over manner to 13 persons over 3 visits to the lab, in either 3g of the ginseng body or 3g of the ginseng rootlets. Ginseng was found to reduce post-prandial glucose when administered as the body, but the rootlets with a higher ginsengoside content were unable to do so.
In type II diabetics given Panax Ginseng at 100-200mg for a period of 8 weeks, improvements in body weight, mood, and glycemic profiles were seen.
Effects Of Korean Red Ginseng On Cardiovascular Risks In Subjects With Metabolic Syndrome: A Double-blind Randomized Controlled Study
12 weeks of 4.5g KRG supplementation in persons with metabolic syndrome noted an increase in HDL-C, but other parameters tested were either not affected or affected to the same extent in placebo
Ginseng And Ginsenoside Re Do Not Improve β-cell Function Or Insulin Sensitivity In Overweight And Obese Subjects With Impaired Glucose Tolerance Or Diabetes
3g of ginseng daily for 2 weeks, and then 8g for the next two weeks, in obese diabetic (or pre-diabetic) adults for 30 days was unable to alter fasting glucose and fasting insulin sensitivity, as well as B-cell function. No circulating levels of ginsenosides were seen despite being advised to consume their final dose 30 minutes before testing.
64 subjects were divided into placebo or experimental, and the latter given 3g of red ginseng extract for 3 months. Although reductions in blood pressure and improvements in heart health were seen with Ginseng, these were also found in placebo.
Effects Of Panax Ginseng Supplementation On Muscle Damage And Inflammation After Uphill Treadmill Running In Humans
Insulin sensitivity was improved and glucose reduced during an Oral Glucose Tolerance Test (OGTT) and muscle damage induced by downhill running was reduced and inflammation production hindered (assessed via IL-6), after consumption of 20g Red Ginseng extract daily in young healthy athletes.
Panax Ginseng Has No Effect On Indices Of Glucose Regulation Following Acute Or Chronic Ingestion In Healthy Volunteers
Two separate studies by the same research group demonstrated that Panax Ginseng had no effect on HbA1c, fasting insulin, or fasting glucose in healthy volunteers.
17mmol Magnesium Orotate daily for 4 weeks was associated with significant improvement on the time it took to complete triathalon-like testing.
Oral Magnesium Supplementation Improves Insulin Sensitivity And Metabolic Control In Type 2 Diabetic Subjects: A Randomized Double-blind Controlled Trial
Magnesium chloride, when correcting a deficiency, is associated with improvements in insulin sensitivity, glucose, and HbA1c. 2.5g Magnesium chloride equates to 450mg elemental magnesium
Effects Of Oral Magnesium Supplementation On Insulin Sensitivity And Blood Pressure In Normo-magnesemic Nondiabetic Overweight Korean Adults
No significant effects were observed in persons with normal magnesium status and without hypertension or pre-diabetes when dosed at 300mg daily
360mg Magnesium daily for 3 months in type II diabetics failed to find any influence on measured parameters.
Magnesium Improves The Beta-cell Function To Compensate Variation Of Insulin Sensitivity: Double-blind, Randomized Clinical Trial
Correcting a magnesium deficiency in nondiabetic and normotensive men (0.66mM to 0.78mM) corrects various pancreatic abnormalities and blood pressure, but no significant influence on weight or triglycerides was noted and the increase in HDL-C failed to reach statistical significance after 3 months.
The Effect Of Magnesium Supplementation On Glucose And Insulin Levels Of Tae-kwan-do Sportsmen And Sedentary Subjects
Glucose was increased at rest and post-fatigue in sportsmen given magnesium relative to sportsmen controls, dose was not given, but was used for 4 weeks.
Oral Magnesium Supplementation Reduces Insulin Resistance In Non-diabetic Subjects - A Double-blind, Placebo-controlled, Randomized Trial
Pre-diabetic (insulin resistant obese persons) that were not magnesium deficient experienced a reduction in fasting blood glucose after 365mg Magnesium Aspartate-Chloride for 6 months. Serum ionized magnesium increased, but erythrocytic and serum were not significant,.
The Effect Of Lowering Blood Pressure By Magnesium Supplementation In Diabetic Hypertensive Adults With Low Serum Magnesium Levels: A Randomized, Double-blind, Placebo-controlled Clinical Trial
A very small increase in HDL but significant reductions in blood pressure observed after 450mg supplementation for 4 months in hypertensive adults with diabetes and low magnesium levels
Oral Zinc Supplementation Does Not Improve Oxidative Stress Or Vascular Function In Patients With Type 2 Diabetes With Normal Zinc Levels
Supplementation of 240mg elemental zinc as gluconate daily for a period of three months in diabetics has failed to provide any additional benefit to circulating biomarkers when the participants were already at adequate zinc stores.
Effect Of Zinc Supplementation On Markers Of Insulin Resistance, Oxidative Stress, And Inflammation Among Prepubescent Children With Metabolic Syndrome
Supplementation of 20mg elemental zinc daily for 8 weeks in obese adolescents who were insulin resistant noted improvements in all biomarkers of glucose metabolism and inflammatory parameters, and a beneficial change was seen in oxidative biomarkers as well as most of the lipid panel (no influence on HDL-C).
Effect Of Zinc Supplementation On Insulin Resistance And Components Of The Metabolic Syndrome In Prepubertal Obese Children
In obese children given 20mg elemental zinc supplementation daily for eight weeks, supplementation was associated with a betterment of biomarkers of glucose metabolism although it was not associated with weight loss nor lipid profiles.
The body's cells use glucose to produce energy. Glucose comes from food and is stored in the body in the form of glycogen (in the muscles and liver) or circulating glucose (in the blood). Cells need the hormone Insulin to capture glucose molecules. The glucose / insulin balance in the blood is essential for the proper functioning of the body's whole metabolism. A change in this metabolism can lead to serious physiological dysfunctions, leading to the development of chronic non-communicable diseases, such as type II diabetes and cardiovascular diseases. There are several classes of compounds that influence this metabolism, these can increase insulin synthesis and secretion, decrease blood glucose levels, reduce the immediate absorption of carbohydrates, regulate the sensitivity of cells to insulin, among others.
Table of negative interactions
Related videos about Biotin
- ^ a b c Chapman-Smith A1, Cronan JE Jr. Molecular biology of biotin attachment to proteins. J Nutr. (1999)
- ^ a b c d e Lanska DJ. The discovery of niacin, biotin, and pantothenic acid. Ann Nutr Metab. (2012)
- ^ Chapman-Smith A1, Cronan JE Jr. The enzymatic biotinylation of proteins: a post-translational modification of exceptional specificity. Trends Biochem Sci. (1999)
- ^ a b c Tong L. Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci. (2013)
- ^ Knowles JR. The mechanism of biotin-dependent enzymes. Annu Rev Biochem. (1989)
- ^ a b Tong L1, Harwood HJ Jr. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem. (2006)
- ^ Huang CS1, et al. Crystal structure of the alpha(6)beta(6) holoenzyme of propionyl-coenzyme A carboxylase. Nature. (2010)
- ^ Xiang S1, Tong L. Crystal structures of human and Staphylococcus aureus pyruvate carboxylase and molecular insights into the carboxyltransfer reaction. Nat Struct Mol Biol. (2008)
- ^ Depeint F1, et al. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact. (2006)
- ^ a b c d Hymes J1, Wolf B. Human biotinidase isn’t just for recycling biotin. J Nutr. (1999)
- ^ Pispa J. Animal biotinidase. Ann Med Exp Biol Fenn. (1965)
- ^ a b Shriver BJ1, Roman-Shriver C, Allred JB. Depletion and repletion of biotinyl enzymes in liver of biotin-deficient rats: evidence of a biotin storage system. J Nutr. (1993)
- ^ a b Hymes J1, Fleischhauer K, Wolf B. Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. Biochem Mol Med. (1995)
- ^ Kuroishi T1, et al. Biotinylation is a natural, albeit rare, modification of human histones. Mol Genet Metab. (2011)
- ^ Healy S1, et al. Nonenzymatic biotinylation of histone H2A. Protein Sci. (2009)
- ^ a b Eng WK1, et al. Identification and assessment of markers of biotin status in healthy adults. Br J Nutr. (2013)
- ^ Mock NI1, et al. Increased urinary excretion of 3-hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency. Am J Clin Nutr. (1997)
- ^ Mock DM1. Biotin status: which are valid indicators and how do we know. J Nutr. (1999)
- ^ Mock DM1, et al. Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge. Am J Clin Nutr. (2002)
- ^ Nisenson A. Seborrheic dermatitis of infants: treatment with biotin injections for the nursing mother. Pediatrics. (1969)
- ^ Wolf B. Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”. Genet Med. (2012)
- ^ Cowan TM1, Blitzer MG, Wolf B; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genet Med. (2010)
- ^ a b c Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis. (1991)
- ^ Kresge N, Simoni RD, Hill RL. The Discovery of Avidin by Esmond E. Snell. J Biol Chem. (2004)
- ^ Sydenstricker VP, et al. OBSERVATIONS ON THE “EGG WHITE INJURY” IN MAN AND ITS CURE WITH A BIOTIN CONCENTRATE. JAMA. (1942)
- ^ Baugh CM, Malone JH, Butterworth CE Jr. Human biotin deficiency. A case history of biotin deficiency induced by raw egg consumption in a cirrhotic patient. Am J Clin Nutr. (1968)
- ^ WEI RD, WRIGHT LD. HEAT STABILITY OF AVIDIN AND AVIDIN-BIOTIN COMPLEX AND INFLUENCE OF IONIC STRENGTH ON AFFINITY OF AVIDIN FOR BIOTIN. Proc Soc Exp Biol Med. (1964)
- ^ Murthy CV, Adiga PR. Purification of biotin-binding protein from chicken egg yolk and comparison with avidin. Biochim Biophys Acta. (1984)
- ^ White HB 3rd, et al. Biotin-binding protein from chicken egg yolk. Assay and relationship to egg-white avidin. Biochem J. (1976)
- ^ a b Vesely DL, Kemp SF, Elders MJ. Isolation of a biotin receptor from hepatic plasma membranes. Biochem Biophys Res Commun. (1987)
- ^ Leamon CP1, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. (1991)
- ^ Wuerges J1, Geremia S, Randaccio L. Structural study on ligand specificity of human vitamin B12 transporters. Biochem J. (2007)
- ^ Horn MA1, Heinstein PF, Low PS. Biotin-mediated delivery of exogenous macromolecules into soybean cells. Plant Physiol. (1990)
- ^ a b Russell-Jones G1, et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem. (2004)
- ^ Yellepeddi VK1, Kumar A, Palakurthi S. Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res. (2009)
- ^ a b Chauhan J, Dakshinamurti K. Role of human serum biotinidase as biotin-binding protein. Biochem J. (1988)
- ^ Said HM1, Redha R, Nylander W. A carrier-mediated, Na+ gradient-dependent transport for biotin in human intestinal brush-border membrane vesicles. Am J Physiol. (1987)
- ^ a b Said HM1, Redha R. Biotin transport in rat intestinal brush-border membrane vesicles. Biochim Biophys Acta. (1988)
- ^ Said HM1, Derweesh I. Carrier-mediated mechanism for biotin transport in rabbit intestine: studies with brush-border membrane vesicles. Am J Physiol. (1991)
- ^ a b c d Balamurugan K1, Ortiz A, Said HM. Biotin uptake by human intestinal and liver epithelial cells: role of the SMVT system. Am J Physiol Gastrointest Liver Physiol. (2003)
- ^ a b c Prasad PD1, et al. Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. J Biol Chem. (1998)
- ^ Subramanian VS1, et al. Membrane targeting and intracellular trafficking of the human sodium-dependent multivitamin transporter in polarized epithelial cells. Am J Physiol Cell Physiol. (2009)
- ^ a b c d e Subramanya SB1, et al. Inhibition of intestinal biotin absorption by chronic alcohol feeding: cellular and molecular mechanisms. Am J Physiol Gastrointest Liver Physiol. (2011)
- ^ Branner GR1, Roth-Maier DA. Influence of pre-, pro-, and synbiotics on the intestinal availability of different B-vitamins. Arch Anim Nutr. (2006)
- ^ Wang H1, et al. Human placental Na+-dependent multivitamin transporter. Cloning, functional expression, gene structure, and chromosomal localization. J Biol Chem. (1999)
- ^ a b c Said HM1, Horne DW, Mock DM. Effect of aging on intestinal biotin transport in the rat. Exp Gerontol. (1990)
- ^ Said HM1, Mock DM, Collins JC. Regulation of intestinal biotin transport in the rat: effect of biotin deficiency and supplementation. Am J Physiol. (1989)
- ^ León-Del-Río A1, Hol-Soto-Borja D, Velázquez A. Studies on the mechanism of biotin uptake by brush-border membrane vesicles of hamster enterocytes. Arch Med Res. (1993)
- ^ a b Zempleni J1, Mock DM. Uptake and metabolism of biotin by human peripheral blood mononuclear cells. Am J Physiol. (1998)
- ^ a b c d e f g Grafe F1, et al. Transport of biotin in human keratinocytes. J Invest Dermatol. (2003)
- ^ a b Makino Y1, et al. Percutaneous absorption of biotin in healthy subjects and in atopic dermatitis patients. J Nutr Sci Vitaminol (Tokyo). (1999)
- ^ a b Gilby ED, Taylor KJ. Ultrasound monitoring of hepatic metastases during chemotherapy. Br Med J. (1975)
- ^ Mock DM1, Lankford GL, Mock NI. Biotin accounts for only half of the total avidin-binding substances in human serum. J Nutr. (1995)
- ^ a b Mock DM1, Lankford GL, Cazin J Jr. Biotin and biotin analogs in human urine: biotin accounts for only half of the total. J Nutr. (1993)
- ^ Zempleni J1, McCormick DB, Mock DM. Identification of biotin sulfone, bisnorbiotin methyl ketone, and tetranorbiotin-l-sulfoxide in human urine. Am J Clin Nutr. (1997)
- ^ Bogusiewicz A1, et al. Biotin accounts for less than half of all biotin and biotin metabolites in the cerebrospinal fluid of children. Am J Clin Nutr. (2008)
- ^ a b Marshall MW, et al. Effects of biotin on lipids and other constituents of plasma of healthy men and women. Artery. (1980)
- ^ Beinlich CJ1, et al. Myocardial metabolism of pantothenic acid in chronically diabetic rats. J Mol Cell Cardiol. (1990)
- ^ Baur B1, Wick H, Baumgartner ER. Na(+)-dependent biotin transport into brush-border membrane vesicles from rat kidney. Am J Physiol. (1990)
- ^ Baur B1, Baumgartner ER. Biotin and biocytin uptake into cultured primary calf brain microvessel endothelial cells of the blood-brain barrier. Brain Res. (2000)
- ^ Said HM1, et al. Transport of biotin in basolateral membrane vesicles of rat liver. Am J Physiol. (1990)
- ^ Grassl SM. Human placental brush-border membrane Na(+)-biotin cotransport. J Biol Chem. (1992)
- ^ Prasad PD1, et al. Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter. Arch Biochem Biophys. (1999)
- ^ a b c Krause KH, et al. Biotin status of epileptics. Ann N Y Acad Sci. (1985)
- ^ a b c d Castro-Gago M1, et al. Serum biotinidase activity in children treated with valproic acid and carbamazepine. J Child Neurol. (2010)
- ^ a b Castro-Gago M1, et al. The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity. J Child Neurol. (2011)
- ^ a b Suchy SF, Wolf B. Effect of biotin deficiency and supplementation on lipid metabolism in rats: cholesterol and lipoproteins. Am J Clin Nutr. (1986)
- ^ a b Larrieta E1, et al. Pharmacological concentrations of biotin reduce serum triglycerides and the expression of lipogenic genes. Eur J Pharmacol. (2010)
- ^ a b Aguilera-Méndez A1, Fernández-Mejía C. The hypotriglyceridemic effect of biotin supplementation involves increased levels of cGMP and AMPK activation. Biofactors. (2012)
- ^ Ha J1, et al. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem. (1994)
- ^ Dokusova OK, Krivoruchenko IV. The effect of biotin on the level of cholesterol in the blood of patients with atherosclerosis and essential hyperlipidemia. Kardiologiia. (1972)
- ^ a b Revilla-Monsalve C1, et al. Biotin supplementation reduces plasma triacylglycerol and VLDL in type 2 diabetic patients and in nondiabetic subjects with hypertriglyceridemia. Biomed Pharmacother. (2006)
- ^ Sarabu R1, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes–a status review. Curr Opin Drug Discov Devel. (2005)
- ^ a b c d Dakshinamurti K, Cheah-Tan C. Liver glucokinase of the biotin deficient rat. Can J Biochem. (1968)
- ^ a b Dakshinamurti K, Tarrago-Litvak L, Hong HC. Biotin and glucose metabolism. Can J Biochem. (1970)
- ^ a b c Spence JT, Koudelka AP. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. J Biol Chem. (1984)
- ^ Agius L. Control of glucokinase translocation in rat hepatocytes by sorbitol and the cytosolic redox state. Biochem J. (1994)
- ^ Davagnino J, Ureta T. The identification of extrahepatic “glucokinase” as N-acetylglucosamine kinase. J Biol Chem. (1980)
- ^ Spence JT, Pitot HC. Induction of lipogenic enzymes in primary cultures of rat hepatocytes. Relationship between lipogenesis and carbohydrate metabolism. Eur J Biochem. (1982)
- ^ Chauhan J1, Dakshinamurti K. Transcriptional regulation of the glucokinase gene by biotin in starved rats. J Biol Chem. (1991)
- ^ Dakshinamurti K, Cheah-Tan C. Biotin-mediated synthesis of hepatic glucokinase in the rat. Arch Biochem Biophys. (1968)
- ^ a b Vilches-Flores A1, et al. Biotin increases glucokinase expression via soluble guanylate cyclase/protein kinase G, adenosine triphosphate production and autocrine action of insulin in pancreatic rat islets. J Nutr Biochem. (2010)
- ^ De La Vega LA1, Stockert RJ. Regulation of the insulin and asialoglycoprotein receptors via cGMP-dependent protein kinase. Am J Physiol Cell Physiol. (2000)
- ^ a b c d Lazo de la Vega-Monroy ML1, et al. Effects of biotin supplementation in the diet on insulin secretion, islet gene expression, glucose homeostasis and beta-cell proportion. J Nutr Biochem. (2013)
- ^ Sasaki Y, et al. Administration of biotin prevents the development of insulin resistance in the skeletal muscles of Otsuka Long-Evans Tokushima Fatty rats. Food Funct. (2012)
- ^ Koutsikos D1, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother. (1990)
- ^ Krause KH, Berlit P, Bonjour JP. Impaired biotin status in anticonvulsant therapy. Ann Neurol. (1982)
- ^ a b Bonjour JP. Vitamins and alcoholism. V. Riboflavin, VI. Niacin, VII. Pantothenic acid, and VIII. Biotin. Int J Vitam Nutr Res. (1980)
- ^ THOMPSON RH, BUTTERFIELD WJ, FRY IK. Pyruvate metabolism in diabetic neuropathy. Proc R Soc Med. (1960)
- ^ a b c d e Xu C1, et al. Selective overexpression of human SIRT1 in adipose tissue enhances energy homeostasis and prevents the deterioration of insulin sensitivity with ageing in mice. Am J Transl Res. (2013)
- ^ Law IK1, et al. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins. Proteomics. (2009)
- ^ Mao J1, et al. aP2-Cre-mediated inactivation of acetyl-CoA carboxylase 1 causes growth retardation and reduced lipid accumulation in adipose tissues. Proc Natl Acad Sci U S A. (2009)
- ^ a b Fukuwatari T1, Wada H, Shibata K. Age-related alterations of B-group vitamin contents in urine, blood and liver from rats. J Nutr Sci Vitaminol (Tokyo). (2008)
- ^ Mock DM1. Skin manifestations of biotin deficiency. Semin Dermatol. (1991)
- ^ a b Gschwandtner M1, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. (2013)
- ^ Ogawa Y1, et al. Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib. Gan To Kagaku Ryoho. (2014)
- ^ Zempleni J1, Hassan YI, Wijeratne SS. Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab. (2008)
- ^ a b Korkmazer N1, et al. Serum and liver tissue biotinidase enzyme activity in rats which were administrated to valproic acid. Brain Dev. (2006)
- ^ a b Arslan M1, et al. The effects of biotin supplementation on serum and liver tissue biotinidase enzyme activity and alopecia in rats which were administrated to valproic acid. Brain Dev. (2009)
- ^ a b c Schulpis KH1, et al. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia. (2001)
- ^ a b Luís PB1, et al. Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients. J Inherit Metab Dis. (2012)
- ^ Comben N, Clark RJ, Sutherland DJ. Clinical observations on the response of equine hoof defects to dietary supplementation with biotin. Vet Rec. (1984)
- ^ CUNHA TJ, LINDLEY DC, ENSMINGER ME. Biotin deficiency syndrome in pigs fed desicated egg white. J Anim Sci. (1946)
- ^ a b c Colombo VE, et al. Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy. J Am Acad Dermatol. (1990)
- ^ Hale G, Wallis NG, Perham RN. Interaction of avidin with the lipoyl domains in the pyruvate dehydrogenase multienzyme complex: three-dimensional location and similarity to biotinyl domains in carboxylases. Proc Biol Sci. (1992)
- ^ a b c Zempleni J, Trusty TA, Mock DM. Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver. J Nutr. (1997)
- ^ a b c Said HM1, et al. Chronic ethanol feeding and acute ethanol exposure in vitro: effect on intestinal transport of biotin. Am J Clin Nutr. (1990)
- ^ FENNELLY J, et al. PERIPHERAL NEUROPATHY OF THE ALCOHOLIC: I, AETIOLOGICAL ROLE OF ANEURIN AND OTHER B-COMPLEX VITAMINS. Br Med J. (1964)